Mei-Ting Vaillancourt

Statistics

Publications

Citations

389

H-Index

Active since

1994

Affiliations

Genomics Institute of the Novartis Research Foundation(Current)

Mei-Ting Vaillancourt is an author at Genomics Institute of the Novartis Research Foundation specializing in oncology, molecular oncology, and tyrosine kinase inhibitors.

Publications per year

1994–2021

Publications

Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer

Ken N. Wills, Daniel C. Maneval, Patricia Menzel et al. · Human Gene Therapy · 1994 · 235 citations

Life Sciences, Molecular Biology, Oncology +13

EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor

Yong Jia, Jose Juarez, Jie Li et al. · Cancer Research · 2016 · 121 citations · Full text

Medicine, Oncology, Pharmacology +14

Structure-Based Design of Selective LONP1 Inhibitors for Probing <i>In Vitro</i> Biology

Laura J. Kingsley, Xiaohui He, Matthew McNeill et al. · Journal of Medicinal Chemistry · 2021 · 23 citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +8

Abstract 1733: EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC

Shailaja Kasibhatla, Jie Li, Celin Tompkins et al. · Cancer Research · 2014 · 10 citations

Medicine, Oncology, Pharmacology +16

1–4 of 4